<DOC>
	<DOCNO>NCT01646034</DOCNO>
	<brief_summary>This study investigate effect high-dose alkylating chemotherapy compare standard chemotherapy part multimodality treatment approach patient oligo-metastatic breast cancer harbor homologous recombination deficiency .</brief_summary>
	<brief_title>High Dose Chemotherapy Oligo-metastatic Homologous Recombination Deficient Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<criteria>Histologically cytologically confirm infiltrate breast cancer Oligometastatic disease define one three metastatic lesion , without primary tumor , local recurrence , locoregional lymph node metastasis , include axillary , parasternal , ipsilateral periclavicular region . All lesion must amenable resection radiotherapy curative intent . Staging examination must include PETscan plus diagnostic CTscan chest abdomen , isotope bone scan . When isotope bone scan doubtful plain radiograph explain abnormality , MRI CTscan affect skeletal region must perform . The tumor must HER2negative ( either score 0 1 immunohistochemistry negative situ hybridization case score 2 3 immunohistochemistry ) . The tumor must ER positive ( ≥ 10 % nuclear stain IHC ) poorly differentiate ( grade 3 ) . ER negative ; rare tumor ERnegative PgRpositive eligible , pattern hormone receptor expression verify NKIAVL reference pathology lab . Known BRCA1 BRCA2 mutation carrier eligible regardless estrogen receptor status tumor . Age ≥ 18 year World Health Organisation ( WHO ) performance status 0 1 Adequate bone marrow function ( ANC ≥ 1.0 x 109/l , platelet ≥ 100 x 109/l ) Adequate hepatic function ( ALAT , ASAT bilirubin ≤ 2.5 time upper limit normal ) Adequate renal function ( creatinine clearance ≥ 60 ml/min ) LVEF ≥ 50 % measure echocardiography MUGA Absence psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule Signed write informed consent Able comply protocol No malignancy breast cancer , unless treat curative intent without use chemotherapy radiation therapy No current pregnancy breastfeeding . Women childbearing potential must use adequate contraceptive protection . No concurrent anticancer treatment investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>oligo metastatic</keyword>
	<keyword>HRD deficiency</keyword>
</DOC>